Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will post its quarterly earnings results on Thursday, November 2nd. Analysts expect Adaptimmune Therapeutics PLC to post earnings of ($0.23) per share for the quarter.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.24). The business had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, analysts expect Adaptimmune Therapeutics PLC to post $-0.99 EPS for the current fiscal year and $-1.00 EPS for the next fiscal year.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 6.97 on Thursday. The firm has a 50-day moving average of $8.04 and a 200-day moving average of $8.04. The stock’s market cap is $651.83 million. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.

ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Set to Announce Earnings on Thursday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/26/adaptimmune-therapeutics-plc-adap-set-to-announce-earnings-on-thursday.html.

Several equities research analysts have recently commented on the stock. SunTrust Banks, Inc. restated a “buy” rating and issued a $10.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Thursday, October 12th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a report on Wednesday, October 4th. Leerink Swann restated an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.58.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.